PREVIEW
OF YOUR NEWS WIDGETDepression news and depression widget
Sunday, October 26, 2008 ( change date )
Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression
Auspex Pharmaceuticals, a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI). Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of Major Depressive Disorder.
Medicalnewstoday.com Sunday, October 26, 2008Health Highlights: Oct. 26, 2008 (HealthDay)
HealthDay - Here are some of the latest health and medical news developments,
compiled by editors of HealthDay:
yahoo.com Sunday, October 26, 2008
INSTALL YOUR WIDGET